STAAR Surgical Company reported second quarter 2026 financial results for the period ended July 3, 2026. Net sales reached $93.5 million, an 111% increase year-over-year from $44.3 million, driven by over 100% growth in China and double-digit gains in the Americas. The company posted net income of $8.1 million, or $0.16 per diluted share, compared to a net loss of $(16.8) million in the prior year period. Adjusted EBITDA improved to $20.0 million from a loss of $(14.8) million. Gross margin expanded to 74.5% from 74.0%. Cash and investments totaled $181.5 million, with no outstanding debt. Warren Foust assumed the role of President and Chief Executive Officer, succeeding Deborah Andrews who continues as CFO. STAAR Surgical Company operates in the medical device industry, specializing in implantable phakic intraocular lenses for vision correction.
